Staging cardiac damage in patients with aortic regurgitation

Data de publicação: Data Ahead of Print:

Autores da FMUP

  • Francisca Almeida Saraiva

    Autor

  • António Sousa Barros

    Autor

  • Ricardo Manuel Alves Monteiro Fontes De Carvalho

    Autor

  • Francisco Pedro Morais Dias De Almeida Sampaio

    Autor

Participantes de fora da FMUP

  • Silva, G
  • Queiros, P
  • Silva, M
  • Ribeiro, J

Unidades de investigação

Abstract

The impact of "downstream" pathophysiological cardiac consequences in aortic regurgitation patients were not well established. The aim of our study was to validate a staging system built for severe aortic stenosis in a large real-world cohort of aortic regurgitation (AR) patients, evaluating the prevalence of different stages of cardiac damage and assess its prognostic impact. Clinical, echocardiographic and outcome data of patients with moderate-severe AR who underwent transthoracic echocardiography between January/2014 and September/2019 were retrospectively analysed. Patients were classified according to the extent of cardiac damage: Stage 0 (no cardiac damage), Stage 1 (left ventricular damage), Stage 2 (mitral valve or left atrial damage), Stage 3 (tricuspid valve or pulmonary artery vasculature damage) and Stage 4 (right ventricular damage). The primary endpoint was all-cause mortality. A total of 571 patients (median age 73, 51% male) were enrolled: Stage 0 (14.0%), Stage 1 (21.5%), Stage 2 (49.2%), Stage 3 (12.3%) and Stage 4 (3.0%). Median follow-up time was 39.5 months (IQR 22.2 to 61.0). At the end of follow-up, cumulative death was significantly higher in more advanced disease stages (log-rank p < 0.001). On multivariable analysis, Stage 3-4 was associated with increased risk of all-cause mortality (HR 3.20; 95% CI 1.48-6.93; p = 0.003). Our study suggests that extra-valvular damage is common in patients with significant AR and that a staging system developed for aortic stenosis also provides prognostic information in these patients. This staging system may be helpful for clinical decision-making regarding the time of valvular intervention. [GRAPHICS] .

Dados da publicação

ISSN/ISSNe:
1569-5794, 1573-0743

International Journal of Cardiovascular Imaging  Springer Netherlands

Tipo:
Article
Páginas:
2645-2653
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 2

Citações Recebidas na Scopus: 7

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • Aortic regurgitation; Aortic valve; Heart valve disease; Staging

Campos de estudo

Financiamento

Proyectos asociados

Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684

Investigador Principal: João Pedro Melo Marques Pinho Ferreira

Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022

Screening of Fabry Disease in Portuguese Patients With Idiopathic Cardiomyopathies (F-CHECK) - NCT05409846

Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes

Estudo Observacional Académico (F-CHECK) . Sanofi . 2022

The Impact of Obesity on Cardiac Function and Morphology in Aortic Stenosis

Investigador Principal: Ricardo Manuel Alves Monteiro Fontes de Carvalho

Estudo Clínico Académico (Obesity) . 2020

Suboptimal control of cardiovascular risk factors in myocardial infarction survivors

Investigador Principal: Ricardo Manuel Alves Monteiro Fontes de Carvalho

Estudo Clínico Académico (myocard) . 2020

Impacto dos acessos femorais guiados por ecografia vs fluoroscopia nas complicações vasculares associadas à implantação de válvula aórtica percutânea

Investigador Principal: Francisco Pedro Morais Dias de Almeida Sampaio

Estudo Clínico Académico . 2021

Cardiovascular Impact of Metabolic Syndrome: From Mechanisms to New Treatment Targets

Investigador Principal: Ricardo Manuel Alves Monteiro Fontes de Carvalho

Estudo Clínico Académico . 2021

Citar a publicação

Partilhar a publicação